Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Arginase in retinopathy.

Narayanan SP, Rojas M, Suwanpradid J, Toque HA, Caldwell RW, Caldwell RB.

Prog Retin Eye Res. 2013 Sep;36:260-80. doi: 10.1016/j.preteyeres.2013.06.002. Epub 2013 Jul 3. Review.

2.

Arginase 2 deficiency prevents oxidative stress and limits hyperoxia-induced retinal vascular degeneration.

Suwanpradid J, Rojas M, Behzadian MA, Caldwell RW, Caldwell RB.

PLoS One. 2014 Nov 6;9(11):e110604. doi: 10.1371/journal.pone.0110604. eCollection 2014.

3.

Vascular dysfunction in retinopathy-an emerging role for arginase.

Caldwell RB, Zhang W, Romero MJ, Caldwell RW.

Brain Res Bull. 2010 Feb 15;81(2-3):303-9. doi: 10.1016/j.brainresbull.2009.08.025. Epub 2009 Sep 6. Review.

4.

Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia.

Sankaralingam S, Xu H, Davidge ST.

Cardiovasc Res. 2010 Jan 1;85(1):194-203. doi: 10.1093/cvr/cvp277.

PMID:
19684035
5.

Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells.

Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G.

Am J Physiol Endocrinol Metab. 2001 Jan;280(1):E75-82.

6.

Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase.

Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L.

FASEB J. 2003 Dec;17(15):2328-30. Epub 2003 Oct 16.

PMID:
14563685
7.

Upregulation of arginase activity contributes to intracellular ROS production induced by high glucose in H9c2 cells.

Zhou L, Sun CB, Liu C, Fan Y, Zhu HY, Wu XW, Hu L, Li QP.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2728-36. eCollection 2015.

8.

Oxidative stress in brain ischemia.

Love S.

Brain Pathol. 1999 Jan;9(1):119-31. Review.

PMID:
9989455
9.

Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?

Pernow J, Jung C.

Cardiovasc Res. 2013 Jun 1;98(3):334-43. doi: 10.1093/cvr/cvt036. Epub 2013 Feb 14. Review.

PMID:
23417041
10.

Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy.

Beauchamp MH, Sennlaub F, Speranza G, Gobeil F Jr, Checchin D, Kermorvant-Duchemin E, Abran D, Hardy P, Lachapelle P, Varma DR, Chemtob S.

Free Radic Biol Med. 2004 Dec 1;37(11):1885-94.

PMID:
15528047
11.

Arginase: an old enzyme with new tricks.

Caldwell RB, Toque HA, Narayanan SP, Caldwell RW.

Trends Pharmacol Sci. 2015 Jun;36(6):395-405. doi: 10.1016/j.tips.2015.03.006. Epub 2015 Apr 27. Review.

12.

Arginine metabolic enzymes, nitric oxide and infection.

Mori M, Gotoh T.

J Nutr. 2004 Oct;134(10 Suppl):2820S-2825S; discussion 2853S. Review.

13.

Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats.

Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, Soucy KG, Santhanam L, Webb A, Camara A, Sikka G, Nyhan D, Shoukas AA, Ilies M, Christianson DW, Champion HC, Berkowitz DE.

J Appl Physiol (1985). 2009 Oct;107(4):1249-57. doi: 10.1152/japplphysiol.91393.2008. Epub 2009 Aug 6.

14.

Inducible nitric oxide synthase mediates retinal apoptosis in ischemic proliferative retinopathy.

Sennlaub F, Courtois Y, Goureau O.

J Neurosci. 2002 May 15;22(10):3987-93.

15.

Arginase: a critical regulator of nitric oxide synthesis and vascular function.

Durante W, Johnson FK, Johnson RA.

Clin Exp Pharmacol Physiol. 2007 Sep;34(9):906-11. Review.

16.
17.

Arginase 2 deficiency reduces hyperoxia-mediated retinal neurodegeneration through the regulation of polyamine metabolism.

Narayanan SP, Xu Z, Putluri N, Sreekumar A, Lemtalsi T, Caldwell RW, Caldwell RB.

Cell Death Dis. 2014 Feb 20;5:e1075. doi: 10.1038/cddis.2014.23.

18.

Arginase as a mediator of diabetic retinopathy.

Patel C, Rojas M, Narayanan SP, Zhang W, Xu Z, Lemtalsi T, Jittiporn K, Caldwell RW, Caldwell RB.

Front Immunol. 2013 Jul 3;4:173. doi: 10.3389/fimmu.2013.00173. eCollection 2013.

20.

Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism.

Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA.

J Immunol. 2001 Dec 1;167(11):6533-44.

Supplemental Content

Support Center